MedPath

(LARS) Score Validation of Turkish Language

Completed
Conditions
LARS - Low Anterior Resection Syndrome
Registration Number
NCT05289531
Lead Sponsor
Ankara University
Brief Summary

Long-term bowel dysfunction after resection for rectal cancer, known as low anterior resection syndrome (LARS), is observed in many patients. The LARS score was developed to measure this syndrome and its impact on quality of life in Danish patients. Recently, English and many other language versions have been validated. The aim of this study was to validate the Turkish translation of the LARS score in Turkish patients who have undergone treatment for rectal cancer.

Detailed Description

A total of 326 patients were reviewed and contacted for the study, and 222 (68%) were eligible for the analyses. The association between the LARS score and quality of life and the test-retest reliability were studied. The intraclass correlation coefficient (ICC) was calculated to understand the degree of reliability.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
222
Inclusion Criteria

The inclusion criteria were

  • rectal adenocarcinoma within 15 cm from the anal verge
  • LAR with either PME or TME.
  • Bowel continuity restored for at least 18 months when invited for the study.
Exclusion Criteria

Exclusion criteria included

  • failed R0 surgery,
  • recurrence or dissemination,
  • having intestinal stoma,
  • previous cancer (except minor skin cancers)
  • dementia and inability to speak Turkish (i.e., the need for a translator during treatment).

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Validity of LARS ScoreFrom Feb 2016 to Feb 2020

The translated questionaire was validated on Turkish speaking patients

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.